+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease



Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease



European Journal of Nuclear Medicine and Molecular Imaging 41(11): 2137-2143



To investigate the relationships among cerebrospinal fluid (CSF) levels of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid peptide and (123)I-FP-CIT uptake. The study included 58 subjects (31 men and 27 women, age 67 ± 9 years) with a clinical diagnosis of Parkinson disease diagnosed according to the United Kingdom Parkinson Disease Society Brain Bank criteria. All subjects underwent a CSF assay 28 ± 3 days before (123)I-FP-CIT SPECT scanning. The relationships were evaluated by means of linear regression analysis and Pearson correlation. Striatal (123)I-FP-CIT was positively related to both t-Tau and p-Tau CSF values with low levels of t-Tau and p-Tau being related to a low uptake of (123)I-FP-CIT. In particular, differences with higher statistical significance were found for the striatum that is contralateral to theside mainly affected on clinical examination (P<0.001) [corrected].No significant relationships were found between Aβ₁₋₄₂ amyloid peptide and (123)I-FP-CIT binding. The results of our study suggest that the presynaptic dopaminergic system is more involved in Parkinson disease patients with lower t-Tau and p-Tau CSF values while values of Aβ₁₋₄₂ amyloid peptide seems not to be related to nigrostriatal degeneration in our series.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052675629

Download citation: RISBibTeXText

PMID: 25007849

DOI: 10.1007/s00259-014-2841-4


Related references

Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging 32(6): 689-695, 2005

Nonmotor symptoms in early- and advanced-stage Parkinson's disease patients on dopaminergic therapy: how do they correlate with quality of life?. Isrn Neurology 2014: 587302, 2014

Measurement of the dopaminergic degeneration in Parkinson's disease with (123I)beta-CIT and SPECT: Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission Suppl. 50: 9-24, 1997

Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission. Supplementum 50: 9, 1997

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurology 70(10): 1277-1287, 2013

Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease. Movement Disorders 24(11): 1669-1675, 2009

[123I]beta-Cit Spect is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry 74(3): 294-298, 2003

123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. Journal of Neural Transmission 108(8-9): 1011-1019, 2001

Cognitive impairment is associated with Hoehn and Yahr stages in early, de novo Parkinson disease patients. Parkinsonism and Related Disorders 41: 86-91, 2017

α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. Frontiers in Molecular Neuroscience 11: 53, 2018

Discordance between measured postural instability and absence of clinical symptoms in Parkinson's disease patients in the early stages of the disease. Movement Disorders 23(3): 366-372, 2008

123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nuclear Medicine Communications 26(5): 421-426, 2005

Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. Journal of Neural Transmission 118(3): 361-369, 2011

Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. Frontiers in Behavioral Neuroscience 9: 253, 2015

Clinical validity of presynaptic dopaminergic imaging with  123 I-ioflupane and noradrenergic imaging with 123 I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiology of Aging 52: 228-242, 2017